2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow deleobuvir: new trials by email Literature Review of deleobuvir trials Research Report on deleobuvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3 Ribavirin, BI 207127 high dose, Faldaprevir - Hepatitis C, Chronic | Phase 2 | Completed | Boehringer Ingelheim | 35 | 2013-04-01 | 2015-11-20 |
| Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection BI 207127, BI 201335, Ribavirin - Hepatitis C, Chronic | Phase 2 | Completed | Boehringer Ingelheim | 488 | 2010-05-01 | 2016-02-01 |
Germany (2) · Spain (2) · United States (2) · Australia (1) · Austria (1) · France (1) · New Zealand (1) · Portugal (1) · Romania (1) · Switzerland (1) · United Kingdom (1)
PMID 23558093, PMID 23944300, PMID 25512403, PMID 26650626, PMID 27140229, PMID 28030579
2009 (1)